Vaxxinity, Inc. (VAXX)
USD 0.05
(200.0%)
USD 0.05
(200.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -56.93 Thousand USD | 99.92% |
| 2022 | -75.21 Million USD | 45.51% |
| 2021 | -138.01 Million USD | -290.13% |
| 2020 | -35.37 Million USD | -148.8% |
| 2019 | -14.21 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q3 | -13.14 Million USD | 5.95% |
| 2023 Q2 | -13.97 Million USD | 24.08% |
| 2023 Q1 | -18.4 Million USD | 10.08% |
| 2023 FY | -56.93 Million USD | 24.3% |
| 2023 Q4 | -11.39 Million USD | 13.34% |
| 2022 Q4 | -20.47 Million USD | -6.34% |
| 2022 Q3 | -19.25 Million USD | -11.41% |
| 2022 Q2 | -17.28 Million USD | 5.38% |
| 2022 Q1 | -18.26 Million USD | 62.1% |
| 2022 FY | -75.21 Million USD | 45.51% |
| 2021 Q4 | -48.19 Million USD | -58.58% |
| 2021 Q3 | -30.38 Million USD | -12.93% |
| 2021 Q2 | -26.91 Million USD | 15.96% |
| 2021 FY | -138.01 Million USD | -290.13% |
| 2021 Q1 | -32.02 Million USD | -151.76% |
| 2020 Q2 | -7.06 Million USD | -190172.16% |
| 2020 FY | -35.37 Million USD | -148.8% |
| 2020 Q1 | -3711.00 USD | 0.0% |
| 2020 Q4 | -12.71 Million USD | 22.75% |
| 2020 Q3 | -16.46 Million USD | -133.18% |
| 2019 FY | -14.21 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | 92.523% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | 99.34% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 99.815% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 99.954% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 99.646% |
| Better Therapeutics, Inc. | -39.76 Million USD | 99.857% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 99.698% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 99.69% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 99.841% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 99.842% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 99.95% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | 97.468% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 99.924% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 99.904% |
| Innovation1 Biotech Inc. | -5.98 Million USD | 99.049% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 99.733% |
| Molecular Templates, Inc. | -8.12 Million USD | 99.299% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 99.625% |
| NexImmune, Inc. | -32.34 Million USD | 99.824% |
| Orgenesis Inc. | -55.36 Million USD | 99.897% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 99.775% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | 27.024% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 99.689% |
| Scopus BioPharma Inc. | -11.6 Million USD | 99.51% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 99.99% |
| Statera Biopharma, Inc. | -174.4 Million USD | 99.967% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 98.413% |
| Trevena, Inc. | -40.28 Million USD | 99.859% |
| Vaccinex, Inc. | -20.25 Million USD | 99.719% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | 95.184% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 99.888% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 99.268% |